IRIS
GERETTI, ANNA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.403
AS - Asia 4.196
EU - Europa 1.094
SA - Sud America 719
AF - Africa 75
OC - Oceania 4
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.493
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.302
SG - Singapore 1.871
HK - Hong Kong 842
CN - Cina 612
BR - Brasile 591
RU - Federazione Russa 420
VN - Vietnam 357
JP - Giappone 278
FI - Finlandia 144
IT - Italia 96
DE - Germania 77
FR - Francia 73
IN - India 59
MX - Messico 58
GB - Regno Unito 56
AR - Argentina 55
SE - Svezia 53
UA - Ucraina 35
CA - Canada 32
ID - Indonesia 27
AT - Austria 25
NL - Olanda 25
ZA - Sudafrica 25
IE - Irlanda 24
BD - Bangladesh 23
PL - Polonia 21
CO - Colombia 18
EC - Ecuador 17
PK - Pakistan 17
IR - Iran 16
ES - Italia 14
IQ - Iraq 14
PY - Paraguay 12
TR - Turchia 12
TN - Tunisia 10
AZ - Azerbaigian 9
CL - Cile 9
CH - Svizzera 7
EG - Egitto 7
KR - Corea 7
PE - Perù 7
JO - Giordania 6
MA - Marocco 6
SA - Arabia Saudita 6
AE - Emirati Arabi Uniti 5
KE - Kenya 5
UY - Uruguay 5
UZ - Uzbekistan 5
VE - Venezuela 5
AU - Australia 4
ET - Etiopia 4
LT - Lituania 4
MW - Malawi 4
MY - Malesia 4
OM - Oman 4
PH - Filippine 4
TT - Trinidad e Tobago 4
AL - Albania 3
CM - Camerun 3
CR - Costa Rica 3
DO - Repubblica Dominicana 3
HR - Croazia 3
NP - Nepal 3
RO - Romania 3
DZ - Algeria 2
GH - Ghana 2
HU - Ungheria 2
IL - Israele 2
MT - Malta 2
SN - Senegal 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
TW - Taiwan 2
XK - ???statistics.table.value.countryCode.XK??? 2
ZW - Zimbabwe 2
AM - Armenia 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
CG - Congo 1
CI - Costa d'Avorio 1
DK - Danimarca 1
IS - Islanda 1
JM - Giamaica 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LV - Lettonia 1
MD - Moldavia 1
NE - Niger 1
PS - Palestinian Territory 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 10.493
Salva come PNG Salva come JPEG
Città #
Hong Kong 827
San Jose 823
Singapore 647
Woodbridge 565
Houston 501
Wilmington 472
Tokyo 273
Council Bluffs 216
Ashburn 188
Beijing 159
Los Angeles 145
The Dalles 133
Ho Chi Minh City 119
Helsinki 114
Redondo Beach 99
Buffalo 91
Dallas 90
Fairfield 76
Hanoi 70
Moscow 67
Chicago 58
Ann Arbor 56
Mexico City 37
Seattle 34
São Paulo 33
North Bergen 32
Santa Clara 32
Cambridge 30
Lauterbourg 30
New York 25
Jacksonville 24
Rome 24
Dublin 22
Lappeenranta 22
Salt Lake City 21
Haiphong 17
Frankfurt am Main 15
Orem 15
Tehran 15
Johannesburg 14
Medford 14
Nuremberg 14
Phoenix 14
Rio de Janeiro 14
Chandler 13
Elk Grove Village 13
Kraków 13
Stockholm 13
Da Nang 12
London 12
Shaoxing 12
Amsterdam 11
Belo Horizonte 11
Dearborn 11
Brasília 10
Atlanta 9
Changsha 9
Hefei 9
Sterling 9
Vienna 9
Baku 8
Denver 8
Guarulhos 8
Quito 8
Ribeirão Preto 8
Salvador 8
Tampa 8
Biên Hòa 7
Chennai 7
Dulles 7
Fortaleza 7
Lawrence 7
Menlo Park 7
Munich 7
Zhengzhou 7
Ajax 6
Baghdad 6
Bologna 6
Bắc Ninh 6
Curitiba 6
Jakarta 6
Lima 6
Miami 6
Montreal 6
Santiago 6
São Luís 6
Zurich 6
Ankara 5
Bauru 5
Bogotá 5
Buenos Aires 5
Bắc Giang 5
Campinas 5
Charlotte 5
Delhi 5
Duque de Caxias 5
Düsseldorf 5
Guangzhou 5
Hải Dương 5
Manchester 5
Totale 6.712
Salva come PNG Salva come JPEG
Nome #
When and how to use maraviroc in HIV-infected patients 454
European guidelines on the clinical management of HIV-1 tropism testing 446
Emerging patterns and implications of HIV-1 integrase inhibitor resistance 398
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: A multicohort European case-control study using centralized ultrasensitive 454 pyrosequencing 395
Optimal use of maraviroc in clinical practice 375
Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants 257
The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis 253
Low-frequency HIV-1 drug resistance mutations can be clinically significant but must be interpreted with caution 184
Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy 174
Health-related quality-of-life of people with HIV in the era of combination antiretroviral treatment: A cross-sectional comparison with the general population 91
2024 European guidelines for the management of genital herpes 85
Utility of accessible SARS-CoV-2 specific immunoassays in vaccinated adults with a history of advanced HIV infection 84
A contaminant-free assessment of Endogenous Retroviral RNA in human plasma 79
The evolving landscape of COVID-19: Factors associated with in-hospital COVID-19 related mortality during the 2023-2024 phase of JN.1 subvariant dominance 75
A systematic review of hepatitis B virus (HBV) drug and vaccine escape mutations in Africa: A call for urgent action 75
Diagnostic performance evaluation of hepatitis B e antigen rapid diagnostic tests in Malawi 71
Research news in clinical context 70
Plasma HIV-1 RNA detection below 50 copies/mL and risk of virologic rebound in patients receiving highly active antiretroviral therapy 68
The intrahepatic activity of Hepatitis Delta virus is sustained by an abundant production of HBs transcripts, mainly derived from integrated HBV-DNA, and is not strictly related to the extent of HBV reservoir 68
PATHWAYS UNDERLYING HDV PERSISTENCE ACT INDEPENDENTLY FROM THE EXTENT OF HBV RESEVOIR AND ARE SUSTAINED BY AN ABUNDANT PRODUCTION OF HBSAG DERIVED FROM INTEGRATED HBV-DNA P 214 65
British HIV Association Guidelines on the Use of Vaccines in HIV-Positive Adults 2015 64
Epidemiology of hepatitis B, C and D in Malawi: Systematic review 11 Medical and Health Sciences 1117 Public Health and Health Services 11 Medical and Health Sciences 1108 Medical Microbiology 11 Medical and Health Sciences 1103 Clinical Sciences 64
A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a high barrier to the emergence of resistance mutations in protease but identifies alternative pathways of resistance 62
Alcohol, smoking, recreational drug use and association with virological outcomes among people living with HIV: cross-sectional and longitudinal analyses 58
Antiretroviral drug resistance in HIV-1-infected patients with low-level viremia 56
Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study 55
Determining virological suppression and resuppression by point-of-care viral load testing in a HIV care setting in sub-Saharan Africa 55
Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom 53
A clinical and molecular epidemiological survey of hepatitis C in Blantyre, Malawi, suggests a historic mechanism of transmission 51
Chronic HDV infection is sustained by an intense HBsAg production fromintegrated HBVDNA in the setting of a limited or even absent HBV reservoir. 51
Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitor-Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis 51
HBsAg production from integrated HBV-DNA sustains HDV persistence in the setting of a limited or even absent HBV reservoir 51
HDV persistence is sustained by HBsAg mainly derived from integrated HBV-DNA and is independent from the extent of HBV reservoir 51
Pathways sustaining HDV activity act independently from the size of HBV resevoir and are fueled by an abundant expression of HBsAg from integrated HBV-DNA 51
Factors associated with persistence of plasma HIV-1 RNA during long-term continuously suppressive firstline antiretroviral therapy 50
Age, time living with diagnosed HIV infection, and self-rated health 49
A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-na{\"i}ve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): Study protocol for a randomised trial 47
Safety and pharmacokinetic characterization of nacubactam, a novel ?-lactamase inhibitor, alone and in combination with meropenem, in healthy volunteers 46
Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy 46
2014 European guideline on HIV testing 45
Primary herpes simplex virus type-2 infection as a cause of liver failure after liver transplantation 45
Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIVPositive adults receiving first-line antiretroviral therapy in Malawi 45
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook 44
HBV-RNA Co-amplification May Influence HBV DNA Viral Load Determination 44
During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ 44
Attitudes of people in the UK with HIV who are antiretroviral (ART) na{\"i}ve to starting art at high CD4 counts for potential health benefit or to prevent HIV transmission 43
Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz 43
A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients 42
The gamma-glutamyl transpeptidase to platelet ratio (GPR) shows poor correlation with transient elastography measurements of liver fibrosis in HIV-positive patients with chronic hepatitis B in West Africa. Response to: {'}The gamma-glutamyl transpeptidase to platelet ratio (GPR) predicts significant liver fibrosis and cirrhosis in patients with chronic HBV infection in West Africa{'} by Lemoine et al 42
Causes, associated exposures, and outcomes of cirrhosis and hepatocellular carcinoma in Malawi: an observational cohort and case–control study 42
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight) 41
HIV-1 subtypes: Epidemiology and significance for HIV management 41
Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation 40
Cytotoxic T lymphocytes in AIDS pathogenesis: Lessons to be learned from the macaque model of simian immunodeficiency virus infection 40
Outcomes of switching from protease inhibitor-based antiretroviral therapy to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in virologically suppressed adults with nucleos(t)ide analogue resistance- a phase IV randomised, open-label study (PIBIK study). 40
Occult hepatitis B virus coinfection in HIV-positive African migrants to the UK: A point prevalence study 39
Hepatitis B virus infection in general practice across England: An analysis of the Royal College of General Practitioners Research and Surveillance Centre real-world database 39
Recreational drug use, polydrug use, and sexual behaviour in HIV-diagnosed men who have sex with men in the UK: Results from the cross-sectional ASTRA study 39
Optimizing the Use of Cabotegravir Plus Rilpivirine Long-acting Therapy in HIV Care: Evidence, Implementation, and Unanswered Questions 39
British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008 39
Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data 39
An apparent paradox: Resistance mutations in HIV-1 DNA predict improved virological responses to antiretroviral therapy 38
2017 European guidelines for the management of genital herpes 38
Accuracy of self-report of HIV viral load among people with HIV on antiretroviral treatment 38
Discordant CSF/plasma HIV-1 RNA in patients with unexplained low-level viraemia 38
Integrase inhibitor (INI) genotypic resistance in treatment-naive and raltegravir-experienced patients infected with diverse HIV-1 clades 38
Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment 38
Antiretroviral resistance 38
The impact of HIV drug resistance testing on changes to treatment 38
Patterns of HIV testing at a London teaching hospital between 2004 and 2007 38
Socioeconomic status and treatment outcomes for individuals with HIV on antiretroviral treatment in the UK: cross-sectional and longitudinal analyses 38
A virological perspective on resistance in highly treatment-experienced patients 37
Detection of highly prevalent hepatitis B virus coinfection among HIV-seropositive persons in Ghana 37
Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa 37
HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults 37
Role of the coinhibitory receptor cytotoxic T lymphocyte antigen-4 on apoptosis-Prone CD8 T cells in persistent hepatitis B virus infection 37
Prospective pilot study on the relationship between seminal HIV-1 shedding and genital schistosomiasis in men receiving antiretroviral therapy along Lake Malawi 36
Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation 36
Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal 36
IAPAC guidelines for optimizing the HIV care continuum for adults and adolescents 36
Antiretroviral resistance in clinical practice 35
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 35
Kinetics and Specificities of the T Helper?Cell Response to GP120 in the Asymptomatic Stage of HIV-1 Infection 35
Chasing the infecting HIV-1 35
Emergent Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens 35
National survey of diagnostic services for genital herpes 35
Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors 35
Antibody screening tests variably overestimate the prevalence of hepatitis C virus infection among HIV-infected adults in Ghana 35
Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: A systematic review and pooled analysis 35
Low-level viraemia on HAART: Significance and management 34
HIV phylogenetics 34
Responses to switching to maraviroc-based antiretroviral therapy in treated patients with suppressed plasma HIV-1-RNA load 34
The effect of primary drug resistance on CD4 cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy 34
Measuring Proviral HIV-1 DNA: Hurdles and Improvements to an Assay Monitoring Integration Events Utilising Human Alu Repeat Sequences 34
Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5) 34
Evidence for onward transmission of HIV-1 non-B subtype strains in the United Kingdom 34
Adenovirus viraemia and dissemination unresponsive to antiviral therapy in advanced HIV-1 infection [9] 34
CROI 2025 BHIVA working group summary 34
Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK 33
Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring 33
Totale 7.089
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.922
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.922
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202131 0 0 0 0 0 0 0 0 0 11 13 7
2021/202286 3 6 17 2 1 8 3 7 15 4 4 16
2022/202357 8 0 0 6 4 20 6 2 5 0 6 0
2023/202419 3 0 0 0 0 2 0 0 0 10 0 4
2024/20253.043 6 36 28 10 3 59 67 716 886 271 575 386
2025/20266.237 503 473 864 441 413 177 692 1.029 1.145 500 0 0
Totale 11.336